EQ

Over the past six months, Equillium's stock price has trended upwards. In May 2026, inducement grants were reported, and the company participated in Oppenheimer's 2026 Innovation on the Island Event. In April 2026, poster presentations were announced at IMMUNOLOGY2026™, and SEC filings indicated a stake by Aberdeen Group, an effectiveness order, an annual report, and a proxy statement regarding a reverse split and share increase. B.Riley, Raymond James, Roth/MKM, and Stifel initiated coverage with positive ratings. In March 2026, Equillium reported its Fourth Quarter and Full Year 2025 financial results, including no revenue in 2025, a net loss, and the completion of a private placement, and participated in the 38th Annual Roth Conference. In November 2025, the company discussed Aryl Hydrocarbon Receptor as a Drug Target and the EQ504 Program in Immune-Mediated Diseases.